Add to ORKGThis article is based on the ECTRIMS lecture given at the 25(th) ECTRIMS meeting which was held in Dusseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: ( 1) safeguarding the principles of medical ethics; ( 2) optimizing the risk/benefit ratio; ( 3) bridging the gap between multiple sclerosis and experimental autoimmune encephalitis; ( 4) promoting neuroprotection and repair; and ( 5) tailoring multiple sclerosis therapy to the individual patient. Each of these challenges will be discussed and placed in the context of current research into the pathogenesis and treatment of multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous syste...
Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. ...
Multiple sclerosis (MS) is an inflammatory and neurodegenerative demyelinating disease of the centra...
This article is based on the ECTRIMS lecture given at the 25(th) ECTRIMS meeting which was held in D...
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düs...
The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of F...
The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The ‘‘MS...
The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host ...
Introduction. There are not many conditions in which the last few decades have brought such a major ...
The "MS in the 21st Century" initiative was established with the purpose of (1) defining how multipl...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial...
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system ...
Multiple sclerosis (MS) is the commonest disabling neurological condition to afflict young adults an...
Research and advances in the treatment of Multiple Sclerosis (MS) is a story of growing success. Gre...
AbstractMultiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous ...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous syste...
Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. ...
Multiple sclerosis (MS) is an inflammatory and neurodegenerative demyelinating disease of the centra...
This article is based on the ECTRIMS lecture given at the 25(th) ECTRIMS meeting which was held in D...
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düs...
The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of F...
The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The ‘‘MS...
The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host ...
Introduction. There are not many conditions in which the last few decades have brought such a major ...
The "MS in the 21st Century" initiative was established with the purpose of (1) defining how multipl...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial...
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system ...
Multiple sclerosis (MS) is the commonest disabling neurological condition to afflict young adults an...
Research and advances in the treatment of Multiple Sclerosis (MS) is a story of growing success. Gre...
AbstractMultiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous ...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous syste...
Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central nervous system. ...
Multiple sclerosis (MS) is an inflammatory and neurodegenerative demyelinating disease of the centra...